Abstract:Acute myeloid leukemia (AML) is a common type of adult leukemia, and its incidence increases with age, with a poor overall prognosis [ 1 ]. The incidence of AML in the USA is approximately 4.3/100 000, with a 5-year survival rate of about 24% [ 1 ]. Most AML patients experience relapse within 12 months after treatment, but the risk of relapse decreases over time [ 2 ]. According to the European LeukemiaNet (ELN) scoring system for prognosis evaluation of relapsed young AML patients (age ≤ 60), the proportion of high-risk relapsed AML patients is 66%, with 1-year and 5-year overall survival rates of 16% and 4% respectively [ 3 ]. ELN confirmed that shorter time to relapse, adverse genetic characteristics, and older age at relapse are positively correlated with poor prognosis. With current treatment methods, the complete remission rate (CR) of AML can reach 50–80%, but more than 20% of AML patients still cannot achieve CR. Furthermore, most AML patients who achieve CR will still experience relapse, leading to clinically relapsed/refractory AML [ 4 ]. In AML patients who are not suitable for intensive chemotherapy, hypomethylating agents (azacitidine and decitabine) alone or in combination with FLT3 inhibitors, IDH1/2 inhibitors, or BCL2 inhibitors are used as standard treatment regimens [ 2 ]. At present, targeted therapy combined with hypomethylating agents remains the main treatment approach in relapsed/refractory AML patients [ 5 ]. DNA methyltransferase 1 (DNMT1) is a member of the DNMT family, unlike DNMT3A and DNMT3B, which de novo synthesize DNA methylation patterns, DNMT1 is responsible for introducing methylation into the daughter strand after DNA replication [ 6 ]. Members of the DNMT family are closely associated with the progression of AML, and inhibiting the function of DNMT1 significantly reduces the methylation level of the daughter strand, thereby inhibiting the malignant phenotype of AML [ 6 ]. In AML cell and animal models, the robust loss of DNA methylation, transcriptional activation, and inhibition of cancer cell growth are induced by a reversible DNMT1-selective inhibitor that competes with the active-site loop of DNMT1 to penetrate hemi-methylated DNA between two CpG base pairs [ 7 ]. In addition, DNMT1 could be a potential synthetic lethal target in AML cases with DNMT3A mutation [ 8 ].

Targeting DNA methyltransferases for cancer therapy

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferase inhibitors

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Dna Methyltransferases in Hematologic Malignancies

DNA Methyltransferase Inhibitors: Catalysts for Antitumour Immune Responses

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy

Recent progress in DNA methyltransferase inhibitors as anticancer agents

DNA Hypermethylation As a Chemotherapy Target.

DNA Methyltransferases: A Novel Target for Prevention and Therapy

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Emerging role of different DNA methyltransferases in the pathogenesis of cancer

Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy

Targeting tumor endothelial cells with methyltransferase inhibitors: Mechanisms of action and the potential of combination therapy

Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: Mechanisms insights and efficiencies

Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia

Targeting DNA Methylation Machinery in Pediatric Solid Tumors